Cargando…
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. O...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271678/ https://www.ncbi.nlm.nih.gov/pubmed/35832177 http://dx.doi.org/10.3389/fneur.2022.913616 |
_version_ | 1784744721088774144 |
---|---|
author | Ziemssen, Tjalf Richter, Stephan Mäurer, Mathias Buttmann, Mathias Kreusel, Boris Poehler, Anne-Maria Lampl, Maren Linker, Ralf A. |
author_facet | Ziemssen, Tjalf Richter, Stephan Mäurer, Mathias Buttmann, Mathias Kreusel, Boris Poehler, Anne-Maria Lampl, Maren Linker, Ralf A. |
author_sort | Ziemssen, Tjalf |
collection | PubMed |
description | BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. OzEAN is an ongoing study to assess the real-world persistent use, effectiveness, and safety of ozanimod and its impact on quality of life (QoL) in patients with RRMS over a 5-year period. METHODS: This prospective, noninterventional, postmarketing authorization study will enroll ~1,300 patients (≥18 years of age) with active RRMS. The decision to initiate ozanimod must have been made before and independent from study participation. Enrollment began in March 2021. Recruitment is ongoing and will last for 36 months across 140 sites in Germany. Treatment-naive patients or those having prior experience with a disease-modifying therapy receive oral ozanimod 0.92 mg/day after an initial dose escalation, per the summary of product characteristics recommendations, for up to 60 months. Persistence with ozanimod treatment (primary endpoint) is assessed at month 60. Secondary endpoints include additional physician-reported outcomes [persistence at earlier time points, annualized relapse rate, Expanded Disability Status Scale score, cognition (Symbol Digit Modalities Test), and incidence of adverse events], and patient-reported outcomes assessing patient satisfaction, adherence, and treatment modalities (Treatment Satisfaction Questionnaire for Medication, v1.4), disability (United Kingdom Neurological Disability Rating Scale), QoL (MSQOL-54 questionnaire), fatigue (Fatigue Scale for Motor and Cognitive Functions), and health economics [Work Productivity and Activity Impairment Questionnaire for Multiple Sclerosis (German v2.1); Multiple Sclerosis Health Resource Survey, v3.0]. A Multiple Sclerosis Documentation System with an internet-based e-health portal allows patients to view files and complete questionnaires. A safety follow-up will occur 3–8 months after the last ozanimod dose for patients who discontinue treatment early. Long-term results are anticipated after study completion in 2029. Yearly interim analyses are planned after enrollment has reached 25%. CONCLUSION: This is the first long-term, real-world study of ozanimod in patients with RRMS and, to our knowledge, the first noninterventional study utilizing a patient portal. These data will add to the safety/efficacy profile of ozanimod demonstrated in phase 3 trials. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, identifier: NCT05335031. |
format | Online Article Text |
id | pubmed-9271678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92716782022-07-12 OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany Ziemssen, Tjalf Richter, Stephan Mäurer, Mathias Buttmann, Mathias Kreusel, Boris Poehler, Anne-Maria Lampl, Maren Linker, Ralf A. Front Neurol Neurology BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. OzEAN is an ongoing study to assess the real-world persistent use, effectiveness, and safety of ozanimod and its impact on quality of life (QoL) in patients with RRMS over a 5-year period. METHODS: This prospective, noninterventional, postmarketing authorization study will enroll ~1,300 patients (≥18 years of age) with active RRMS. The decision to initiate ozanimod must have been made before and independent from study participation. Enrollment began in March 2021. Recruitment is ongoing and will last for 36 months across 140 sites in Germany. Treatment-naive patients or those having prior experience with a disease-modifying therapy receive oral ozanimod 0.92 mg/day after an initial dose escalation, per the summary of product characteristics recommendations, for up to 60 months. Persistence with ozanimod treatment (primary endpoint) is assessed at month 60. Secondary endpoints include additional physician-reported outcomes [persistence at earlier time points, annualized relapse rate, Expanded Disability Status Scale score, cognition (Symbol Digit Modalities Test), and incidence of adverse events], and patient-reported outcomes assessing patient satisfaction, adherence, and treatment modalities (Treatment Satisfaction Questionnaire for Medication, v1.4), disability (United Kingdom Neurological Disability Rating Scale), QoL (MSQOL-54 questionnaire), fatigue (Fatigue Scale for Motor and Cognitive Functions), and health economics [Work Productivity and Activity Impairment Questionnaire for Multiple Sclerosis (German v2.1); Multiple Sclerosis Health Resource Survey, v3.0]. A Multiple Sclerosis Documentation System with an internet-based e-health portal allows patients to view files and complete questionnaires. A safety follow-up will occur 3–8 months after the last ozanimod dose for patients who discontinue treatment early. Long-term results are anticipated after study completion in 2029. Yearly interim analyses are planned after enrollment has reached 25%. CONCLUSION: This is the first long-term, real-world study of ozanimod in patients with RRMS and, to our knowledge, the first noninterventional study utilizing a patient portal. These data will add to the safety/efficacy profile of ozanimod demonstrated in phase 3 trials. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, identifier: NCT05335031. Frontiers Media S.A. 2022-06-27 /pmc/articles/PMC9271678/ /pubmed/35832177 http://dx.doi.org/10.3389/fneur.2022.913616 Text en Copyright © 2022 Ziemssen, Richter, Mäurer, Buttmann, Kreusel, Poehler, Lampl and Linker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Ziemssen, Tjalf Richter, Stephan Mäurer, Mathias Buttmann, Mathias Kreusel, Boris Poehler, Anne-Maria Lampl, Maren Linker, Ralf A. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title | OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title_full | OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title_fullStr | OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title_full_unstemmed | OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title_short | OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany |
title_sort | ozean study to collect real-world evidence of persistent use, effectiveness, and safety of ozanimod over 5 years in patients with relapsing-remitting multiple sclerosis in germany |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271678/ https://www.ncbi.nlm.nih.gov/pubmed/35832177 http://dx.doi.org/10.3389/fneur.2022.913616 |
work_keys_str_mv | AT ziemssentjalf ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT richterstephan ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT maurermathias ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT buttmannmathias ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT kreuselboris ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT poehlerannemaria ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT lamplmaren ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany AT linkerralfa ozeanstudytocollectrealworldevidenceofpersistentuseeffectivenessandsafetyofozanimodover5yearsinpatientswithrelapsingremittingmultiplesclerosisingermany |